Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
PHASE1CompletedINTERVENTIONAL
Timeline
Start Date
January 31, 2000
Primary Completion Date
October 31, 2002
Study Completion Date
October 31, 2002
Conditions
LeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmProstate CancerSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG
vorinostat
Trial Locations (1)
10021
Memorial Sloan-Kettering Cancer Center, New York
All Listed Sponsors
collaborator
National Cancer Institute (NCI)
NIH
lead
Memorial Sloan Kettering Cancer Center
OTHER
NCT00005634 - Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy | Biotech Hunter | Biotech Hunter